🚀 VC round data is live in beta, check it out!
Omnicell Valuation Multiples
Discover revenue and EBITDA valuation multiples for Omnicell and similar public comparables like Dis-Chem Pharmacies, LBX Pharmacy, Qingdao Baheal Medical, Hangzhou Pinming Software and more.
Omnicell Overview
About Omnicell
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Founded
1992
HQ
Employees
3.7K
Website
Financials (LTM)
EV
$2B
Omnicell Financials
Omnicell reported last 12-month revenue of $1B and EBITDA of $143M.
In the same LTM period, Omnicell generated $603M in gross profit, $143M in EBITDA, and $76M in net income.
Revenue (LTM)
Omnicell P&L
In the most recent fiscal year, Omnicell reported revenue of $1B and EBITDA of $140M.
Omnicell expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $603M | XXX | $503M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $143M | XXX | $140M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $76M | XXX | $75M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 6% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Omnicell Stock Performance
Omnicell has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Omnicell's stock price is $38.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 1.6% | XXX | XXX | XXX | $1.65 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOmnicell Valuation Multiples
Omnicell trades at 1.4x EV/Revenue multiple, and 12.1x EV/EBITDA.
EV / Revenue (LTM)
Omnicell Financial Valuation Multiples
As of April 18, 2026, Omnicell has market cap of $2B and EV of $2B.
Equity research analysts estimate Omnicell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Omnicell has a P/E ratio of 22.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 12.4x | XXX | XXX | XXX |
| EV/EBIT | 20.1x | XXX | 20.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 3.4x | XXX | XXX | XXX |
| P/E | 22.8x | XXX | 23.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 25.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Omnicell Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Omnicell Margins & Growth Rates
Omnicell's revenue in the last 12 month grew by 5%.
Omnicell's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Omnicell's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Omnicell's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Omnicell Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Omnicell Public Comps
See public comps and valuation multiples for other Healthcare Software and Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Omnicell | XXX | XXX | XXX | XXX | XXX | XXX |
| Dis-Chem Pharmacies | XXX | XXX | XXX | XXX | XXX | XXX |
| LBX Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Qingdao Baheal Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Hangzhou Pinming Software | XXX | XXX | XXX | XXX | XXX | XXX |
| AiN Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Omnicell M&A Activity
Omnicell acquired XXX companies to date.
Last acquisition by Omnicell was on XXXXXXXX, XXXXX. Omnicell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Omnicell
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOmnicell Investment Activity
Omnicell invested in XXX companies to date.
Omnicell made its latest investment on XXXXXXXX, XXXXX. Omnicell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Omnicell
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Omnicell
| When was Omnicell founded? | Omnicell was founded in 1992. |
| Where is Omnicell headquartered? | Omnicell is headquartered in United States. |
| How many employees does Omnicell have? | As of today, Omnicell has over 3K employees. |
| Who is the CEO of Omnicell? | Omnicell's CEO is Randall A. Lipps. |
| Is Omnicell publicly listed? | Yes, Omnicell is a public company listed on Nasdaq. |
| What is the stock symbol of Omnicell? | Omnicell trades under OMCL ticker. |
| When did Omnicell go public? | Omnicell went public in 2001. |
| Who are competitors of Omnicell? | Omnicell main competitors are Dis-Chem Pharmacies, LBX Pharmacy, Qingdao Baheal Medical, Hangzhou Pinming Software. |
| What is the current market cap of Omnicell? | Omnicell's current market cap is $2B. |
| What is the current revenue of Omnicell? | Omnicell's last 12 months revenue is $1B. |
| What is the current revenue growth of Omnicell? | Omnicell revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Omnicell? | Current revenue multiple of Omnicell is 1.4x. |
| Is Omnicell profitable? | Yes, Omnicell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Omnicell? | Omnicell's last 12 months EBITDA is $143M. |
| What is Omnicell's EBITDA margin? | Omnicell's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Omnicell? | Current EBITDA multiple of Omnicell is 12.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.